Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Solid Biosciences Inc.    SLDB

SOLID BIOSCIENCES INC.

(SLDB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 3.86 USD
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 7.58.
  • The company's earnings releases usually do not meet expectations.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
SOLID BIOSCIENCES INC.-10.42%447
-
GILEAD SCIENCES, INC.14.49%83 610
WUXI APPTEC CO., LTD.36.65%64 891
VERTEX PHARMACEUTICALS0.55%61 795
REGENERON PHARMACEUTICALS12.62%57 427
BEIGENE, LTD.38.68%32 675
GENMAB A/S5.56%27 803
BIONTECH SE30.39%25 593
ARGENX SE4.88%14 614
HUALAN BIOLOGICAL ENGINEERI..16.79%13 990
MYOKARDIA, INC.0.00%11 993
-
NEUROCRINE BIOSCIENCES, INC..24.57%10 850
MIRATI THERAPEUTICS, INC.-7.20%10 249
ULTRAGENYX PHARMACEUTICAL I..1.11%9 260
DENALI THERAPEUTICS INC.-12.87%8 752
ASCENDIS PHARMA A/S-6.63%8 410
More Results
Financials (USD)
Sales 2020 - - -
Net income 2020 -87,8 M - -
Net cash 2020 60,6 M - -
P/E ratio 2020 -4,13x
Yield 2020 -
Capitalization 414 M 414 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 121
Free-Float 49,8%
Upcoming event on SOLID BIOSCIENCES INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision -
1 year Revenue revision -
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes